Fate Therapeutics (FATE) Reports In-Line Q4 EPS

Fate Therapeutics (NASDAQ: FATE) reported Q4 EPS of ($0.44), in-line with the analyst estimate of ($0.44). Revenue for the quarter came in at $1.86 million versus the consensus estimate of $1.58 million.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• Fed's Williams: No Need For Urgency After Sept. Rate Increase
• Trump in meeting with AI leaders: we have big lead on AI and want to keep it
• Oura delayed IPO after some investors balked at valuation - report